Setterwalls has advised IRRAS AB in connection with rights issue of approximately SEK 217 million and listing on Nasdaq Stockholm main market

Setterwalls has advised IRRAS AB in connection with rights issue of approximately SEK 217 million and listing on Nasdaq Stockholm main market.

Setterwalls has advised IRRAS AB in connection with a rights issue of approximately SEK 217 million and listing of the company’s ordinary shares on Nasdaq Stockholm main market. IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies.

IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners. The first day of trading on Nasdaq Stockholm’s main market was 20 May 2020.